In conclusion, this study elucidates the mechanism that Cbl alleviates endothelial dysfunction in DM through inhibiting the JAK2/STAT4 pathway and Runx3 expression (Fig. 8), providing novel insight into targeted therapy against DM and comprehensive understanding on DM progression. This evidence concerns the gene RUNX3 and diabetes mellitus.